New hope for rare skin cancer: targeted therapy shows promise in chinese patients
NCT ID NCT05442554
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 34 times
Summary
This study tested a drug called brentuximab vedotin in 10 Chinese adults with a rare type of skin lymphoma (CD30-positive cutaneous T-cell lymphoma). The goal was to see if the drug could shrink or eliminate cancer spots and to check for long-term side effects. Participants received the drug through a vein every 3 weeks for up to 16 cycles. The study is complete, and results help doctors understand how well this treatment works in Chinese patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.